Characterisation of steady‐state pharmacokinetics and glucodynamics of once‐weekly insulin efsitora alfa in individuals with type 2 diabetes
Efsitora demonstrated a flat, prolonged PK profile, providing a consistent level of insulin exposure at steady-state and resulting in a stable glucose-lowering response across the weekly dosing interval.
Authors
- David G. Waters
- Douglas E. James
- Eric Zijlstra (ORCID: https://orcid.org/0000-0001-8843-5452)
- Oliver Klein (ORCID: https://orcid.org/0000-0003-0022-9553)
- MG Case
- Helle Linnebjerg (ORCID: https://orcid.org/0000-0001-5849-921X)
- Tim Heise (ORCID: https://orcid.org/0000-0002-8346-2037)
- Jennifer Leohr (ORCID: https://orcid.org/0000-0001-5434-7905)
- Ryan T. Jarrett (ORCID: https://orcid.org/0000-0002-5822-351X)
- Edward Pratt (ORCID: https://orcid.org/0000-0003-4449-6231)
- J. Bue-Valleskey
- Subha Suriyapperuma
Institutions
- Eli Lilly (United States) (US)
- Profil Institute for Metabolic Research (DE)
Publication Details
- Journal
- Diabetes Obesity and Metabolism
- Published
- 2026-02-23
- DOI
- https://doi.org/10.1111/dom.70585
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 0.00